Celecoxib + tramadol

Unassigned

New Medicines

Acute moderate-to-severe pain

Information

New formulation
Napp
Napp

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Fixed dose combination of anti-inflammatory drug celecoxib that inhibits cyclooxygenase 2 plus tramadol, a centrally acting weak synthetic μ-opioid receptor agonist and to a lesser extent δ- and κ-opioid receptors agonist.
A survey of 975 people in the UK reported that 21% experienced pain every day or on most days. 67% had visited their GP or a walk-in centre, requesting advice about pain relief [1].
Acute moderate-to-severe pain
Oral